Fiche publication
Date publication
août 2020
Journal
British journal of clinical pharmacology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BORG Christophe
,
Mme JACQUIN Marion
,
Dr ROYER Bernard
,
Dr VERNEREY Dewi
,
Dr KIM Stephano
,
Pr SCHMITT Antonin
,
Dr DEMARCHI Martin
,
Mme HENRIQUES Julie
Tous les auteurs :
Royer B, Schmitt A, Nguyen T, Paillard MJ, Jary M, Demarchi M, Vernerey D, Henriques J, Jacquin M, Borg C, Kim S
Lien Pubmed
Résumé
Raltitrexed (RTX) is a thymidylate synthase inhibitor with large pharmacokinetics (PK) variability that can be administered in case of 5-fluorouracil (5FU) intolerance or dihydropyrimidine dehydrogenase deficiency (DPD). While it is a more potent thymidylate synthase inhibitor than 5FU, RTX failed to replace this drug for colorectal cancer patients, mainly due to its toxicity at the recommended dose of 3 mg/m every three weeks. However, every two weeks administration at 2 mg/m demonstrated a favourable toxicity profile.
Mots clés
BSA, clearance, dosing rational, population pharmacokinetics, raltitrexed
Référence
Br J Clin Pharmacol. 2020 Aug 12;:
